Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin in diabetic patients with non-alcoholic fatty liver disease
IRCT20150706023084N18Phase 2Completed
- Sponsor
- Islamic Azad University
- Start
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of empagliflozin in metabolic dysfunction-associated steatotic liver disease (MASLD) and type 2 diabetes mellitus (T2DM), sponsored by Islamic Azad University. Primary endpoints: Fatty liver and Sonographic change in fatty liver. Started Aug 2023; status: completed.
02
Drugs
empagliflozin
03
Conditions
metabolic dysfunction-associated steatotic liver disease (MASLD)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on IRCT20150706023084N18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20150706023084N18.